Skip to content

Stepped Care Model for the Wider Dissemination of Cognitive-Behavioural Therapy for Insomnia Among Cancer Patients

A Stepped Care Model for the Wider Dissemination of Cognitive-Behavioural Therapy for Insomnia Among Cancer Patients : Efficacy and Cost-Effectiveness.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01864720
Acronym
Stepped Care
Enrollment
177
Registered
2013-05-30
Start date
2013-09-30
Completion date
2018-11-30
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Keywords

stepped care model, insomnia, cancer, cognitive-behavioural therapy, self-help treatment, web-based intervention, non-inferiority design, cost-effectiveness

Brief summary

Insomnia is very common in cancer patients. When left untreated, insomnia can lead to numerous serious consequences (e.g., psychological disorders) for the individual and significant costs for society (e.g., increased medical consultations). Cognitive-behavioural therapy (CBT), a form of psychotherapy, is now considered the treatment of choice for insomnia and its efficacy has been demonstrated in clinical studies conducted in cancer patients. Unfortunately, CBT for insomnia (CBT-I) is not widely accessible as only a few cancer clinics have mental health professionals formally trained in the administration of this treatment. Innovative models of treatment delivery are therefore needed to make sure that every cancer patient with insomnia receives the care he/she needs. A stepped care approach in which patients only receive the level of treatment that they need, beginning with a minimal, less costly, intervention followed by more intensive treatment if required, has shown some promises for other psychological disorders (e.g., depression). Although its relevance has been emphasized to make CBT-I more accessible, its utility has never been investigated. The main goal of this randomized non-inferiority study is to assess the efficacy and costeffectiveness of a stepped care CBT-I as compared with standard care. Our hypothesis is that a stepped care approach will not be statistically inferior in terms of efficacy as compared to usual care, while being much less costly (better cost-effectiveness ratio). Three hundred cancer patients (mixed cancer sites) with insomnia symptoms will be assigned to: (1) stepped care CBT-I (n = 118) or (2) standard care (n = 59), consisting of 6 weekly sessions administered individually by a professional.

Interventions

BEHAVIORALProfessionally-administered cognitive-behavioral therapy for insomnia (CBT-I)

The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.

The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
CHU de Quebec-Universite Laval
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* have received a diagnosis of non-metastatic cancer (any type) in the past -18 months * to have an ISI score \> 7 * to be aged between 18 and 75 years old * to be readily able to read and understand French

Exclusion criteria

* having a life expectancy \< 1 year * having a severe psychiatric disorder (e.g., psychotic, substance use, severe depressive disorder) * having severe cognitive impairments (e.g., diagnosis of Parkinson's disease, dementia, or Mini-Mental State Examination score \< 24) * having received a formal diagnosis for another sleep disorder (e.g., obstructive sleep apnea, periodic limb movement disorder) * shift work in the past 3 months or in the next 12 months * to have received a CBT for insomnia in the past

Design outcomes

Primary

MeasureTime frameDescription
Change in Insomnia Severity IndexPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)total score
Change in sleep efficiency (SE) index (%)Pre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)total sleep time/total time spent in bed X 100 - from sleep diary

Secondary

MeasureTime frameDescription
Change in total wake time (TWT) - from sleep diaryPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)summation of SOL, WASO, and early morning awakening - from sleep diary
Change in total sleep time (TST) - from sleep diaryPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)time in bed minus total wake time - from sleep diary
Change in hypnotic use - from sleep diaryPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)use of sleep-promoting medications - from sleep diary
Change in sleep onset latency (SOL) - from actigraphyPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)time to sleep after lights out - from actigraphy
Change in sleep onset latency (SOL) - from sleep diaryPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)time to sleep after lights out - from sleep diary
Change in total wake time (TWT) - from actigraphyPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)summation of SOL, WASO, and early morning awakening - from actigraphy
Change in total sleep time (TST) - from actigraphyPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)time in bed minus total wake time - from actigraphy
Change in sleep efficiency (SE) index (%) - from actigraphyPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)ratio of total sleep time to the actual time spent in bed multiplied by 100
Change in wake after sleep onset (WASO) - from actigraphyPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)summation of nocturnal awakenings - from actigraphy
Change in wake after sleep onset (WASO) - from sleep diaryPre-tx (at recruitment; T1), post-tx (6 weeks after; T2), 3-month FU (T3), 6-month FU (T4), 12-month FU (T5)summation of nocturnal awakenings - from sleep diary

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026